Retraction Note to: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF (Molecular Cancer, (2010), 9, 1, (148), 10.1186/1476-4598-9-148);Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Johnson, Thomas R ^a   Koul, Sweaty ^a   Kumar, Binod ^a   Khandrika, Lakshmipathi ^a   Venezia, Sarah ^a   Maroni, Paul D ^a   Meacham, Randall B ^a   Koul, Hari K ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GELATINASE B; MESSENGER RNA; PROSTATE DERIVED ETS FACTOR; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; PRIMER DNA; SPDEF PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FOCAL ADHESION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ENZYMOLOGY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953447188     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-021-01402-x     Document Type: Erratum

References (27)

1. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94:981-990.
2. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA. PDEF, a novel prostate epithelium-specific transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000, 275:1216-1225. 10.1074/jbc.275.2.1216, 10625666.
3. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 2005, 65:11572-11580. 10.1158/0008-5472.CAN-05-1196, 16357167.
4. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007, 67:1618-1625. 10.1158/0008-5472.CAN-06-2913, 17308102.
5. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007, 67:4219-4226. 10.1158/0008-5472.CAN-06-3689, 17483333.
6. Cho JY, Lee M, Ahn JM, Park ES, Cho JH, Lee SJ, Kim BG, Heo SH, Park HJ, Zerbini LF, Hwang D, Libermann TA. Proteomic Analysis of a PDEF Ets Transcription Factor-Interacting Protein Complex. J Proteome Res 2009, 8:1327-1337. 10.1021/pr800683b, 19203193.
7. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003, 63:4626-4631.
8. Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 2008, 123:1376-1384. 10.1002/ijc.23667, 2827153, 18567002.
9. Turcotte S, Forget MA, Beauseigle D, Nassif E, Lapointe R. Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. Neoplasia 2007, 9:788-796. 10.1593/neo.07460, 2040205, 17971898.
10. Ghadersohi A, Sood AK. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 2001, 7:2731-2738.
11. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 2007, (38:):1628-1638. 10.1016/j.humpath.2007.03.010, 2121591, 17521701.
12. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Meth Enzymol 1987, 146:341-349. Cancer Res. 2008, 68:1777-1785, full_text, 3479675.
13. Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 1989, 9:192-208.
14. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580.
15. Bernhard EJ, Muschel RJ. Ras, metastasis, and matrix metalloproteinase 9. Methods Enzymol 2001, 333:96-103. full_text, 11400358.
16. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/S1046-2023(03)00032-X, 12798140.
17. Koul S, Huang M, Bhat S, Maroni P, Meacham RB, Koul HK. Oxalate exposure provokes HSP 70 response in LLC-PK1 cells, a line of renal epithelial cells: protective role of HSP 70 against oxalate toxicity. Urol Res 2008, 36:1-10. 10.1007/s00240-007-0130-4, 18172632.
18. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68. 10.1038/nrm1549, 15688067.
19. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. Mol Cancer Res 2008, 6:1639-1648. 10.1158/1541-7786.MCR-08-0052, 18922979.
20. Ida K, Kobayashi S, Taki T, Hanada R, Bessho F, Yamamori S, Sugimoto T, Ohki M, Hayashi Y. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor. Int J Cancer 1995, 63:500-504. 10.1002/ijc.2910630407, 7591257.
21. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
22. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001, 2:827-837. 10.1038/35099076, 11715049.
23. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648. 10.1126/science.1117679, 16254181.
24. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008, 68:73-80. 10.1158/0008-5472.CAN-07-5352, 18172298.
25. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA. SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation-Specific Fusion Transcript in Prostate Cancer. Cancer Res 2009, 69:2734-2738. 10.1158/0008-5472.CAN-08-4926, 19293179.
26. Chintala SK, Sawaya R, Aggarwal BB, Majumder S, Giri DK, Kyritsis AP, Gokaslan ZL, Rao JS. Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells. J Biol Chem 1998, 273:13545-13551. 10.1074/jbc.273.22.13545, 9593690.
27. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004, 7:327-332. 10.1038/sj.pcan.4500750, 15356679.